IL270124B1 - - Google Patents

Info

Publication number
IL270124B1
IL270124B1 IL27012419A IL27012419A IL270124B1 IL 270124 B1 IL270124 B1 IL 270124B1 IL 27012419 A IL27012419 A IL 27012419A IL 27012419 A IL27012419 A IL 27012419A IL 270124 B1 IL270124 B1 IL 270124B1
Authority
IL
Israel
Application number
IL27012419A
Other languages
English (en)
Other versions
IL270124A (en:Method
IL270124B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270124A publication Critical patent/IL270124A/en
Publication of IL270124B1 publication Critical patent/IL270124B1/en
Publication of IL270124B2 publication Critical patent/IL270124B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL270124A 2012-11-05 2019-10-23 Genetically modified non-human animals and methods of their use IL270124B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722437P 2012-11-05 2012-11-05
PCT/US2013/068569 WO2014071397A2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Publications (3)

Publication Number Publication Date
IL270124A IL270124A (en:Method) 2019-12-31
IL270124B1 true IL270124B1 (en:Method) 2023-02-01
IL270124B2 IL270124B2 (en) 2023-06-01

Family

ID=49876957

Family Applications (5)

Application Number Title Priority Date Filing Date
IL299887A IL299887B2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
IL311744A IL311744B2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of using them
IL238478A IL238478B (en) 2012-11-05 2015-04-27 Genetically modified non-human animals and methods of their use
IL25896818A IL258968B (en) 2012-11-05 2018-04-26 A method for producing an antibody in a non-human animal
IL270124A IL270124B2 (en) 2012-11-05 2019-10-23 Genetically modified non-human animals and methods of their use

Family Applications Before (4)

Application Number Title Priority Date Filing Date
IL299887A IL299887B2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
IL311744A IL311744B2 (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of using them
IL238478A IL238478B (en) 2012-11-05 2015-04-27 Genetically modified non-human animals and methods of their use
IL25896818A IL258968B (en) 2012-11-05 2018-04-26 A method for producing an antibody in a non-human animal

Country Status (19)

Country Link
US (5) US9901082B2 (en:Method)
EP (5) EP3556206B1 (en:Method)
JP (5) JP6422441B2 (en:Method)
KR (5) KR102275412B1 (en:Method)
CN (3) CN104918483B (en:Method)
AU (3) AU2013337242B2 (en:Method)
CA (1) CA2887706C (en:Method)
DK (5) DK4389764T3 (en:Method)
ES (4) ES2884598T3 (en:Method)
FI (2) FI3939423T3 (en:Method)
IL (5) IL299887B2 (en:Method)
MX (3) MX377561B (en:Method)
MY (1) MY175400A (en:Method)
NO (1) NO2946162T3 (en:Method)
NZ (3) NZ631614A (en:Method)
PT (4) PT3556206T (en:Method)
RU (1) RU2673156C2 (en:Method)
SG (2) SG11201502685XA (en:Method)
WO (1) WO2014071397A2 (en:Method)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
IN2015DN02032A (en:Method) * 2012-09-07 2015-08-14 Univ Yale
ES2884598T3 (es) 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
CA2900832A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
CA2900824A1 (en) 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
MX368931B (es) 2013-09-23 2019-10-22 Regeneron Pharma Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
US20150143558A1 (en) 2013-11-19 2015-05-21 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
BR112016011004A2 (pt) 2013-11-19 2017-12-05 Regeneron Pharma animal roedor geneticamente modificado, célula tronco embrionária de roedor, embrião de roedor, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
RU2700484C2 (ru) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
US20160029604A1 (en) 2014-04-28 2016-02-04 Recombinetics, Inc. Multiplex gene editing
CN106659146B (zh) 2014-05-05 2020-06-23 再生元制药公司 人源化c5和c3动物
NO2785538T3 (en:Method) 2014-05-07 2018-08-04
PT3482629T (pt) * 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
EP3683238A1 (en) 2014-06-19 2020-07-22 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
KR102659123B1 (ko) 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
FI3850946T3 (fi) * 2014-12-05 2023-12-28 Regeneron Pharma Ei-ihmiseläimiä, joilla on humanisoitu erilaistumisklusterin 47 geeni
EP3808775B1 (en) 2014-12-09 2024-04-17 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 274 gene
WO2016137841A1 (en) * 2015-02-26 2016-09-01 William Paterson University Of New Jersey Transgenic mice
RU2732628C2 (ru) 2015-04-06 2020-09-21 Регенерон Фармасьютикалз, Инк. Опосредованные гуманизированными т-клетками иммунные ответы у не относящихся к человеку животных
PT3282835T (pt) * 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
EP3895529B1 (en) 2016-02-29 2026-04-29 Regeneron Pharmaceuticals, Inc. Rodents having a humanized tmprss gene
JP7134944B2 (ja) * 2016-08-11 2022-09-12 ザ ジャクソン ラボラトリー 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US20190320633A1 (en) * 2016-11-30 2019-10-24 The Jackson Laboratory Humanized mouse model with improved human innate immune cell development
CN110461146A (zh) * 2017-02-27 2019-11-15 再生元制药公司 视网膜劈裂的非人类动物模型
CN107115424B (zh) * 2017-05-09 2018-05-29 江西樟树市正康医药生物科技有限公司 改变酸性体质保钙及清热解毒的中药组合物及制备方法
RU2019140867A (ru) 2017-05-12 2021-06-15 Зе Джексон Лаборатори Nsg мыши, не имеющие mhc класса i и класса ii
JP7139419B2 (ja) 2017-09-29 2022-09-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｔｒ遺伝子座を含む非ヒト動物および使用方法
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
EP3768314A4 (en) 2018-03-21 2022-01-05 ALX Oncology Inc. ANTIBODIES AGAINST ALPHA SIGNAL REGULATING PROTEIN AND METHODS OF USE
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
IL315703A (en) 2018-07-16 2024-11-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020074005A1 (en) * 2018-10-12 2020-04-16 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric genes
CN111172190B (zh) * 2018-12-25 2021-07-30 百奥赛图江苏基因生物技术有限公司 人源化细胞因子csf2基因改造非人动物的构建方法及应用
ES2966625T3 (es) 2019-04-04 2024-04-23 Regeneron Pharma Roedores que comprenden un locus del factor de coagulación 12 humanizado
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
CA3137764A1 (en) 2019-06-07 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
WO2021011853A2 (en) * 2019-07-17 2021-01-21 Yale University Genetically modified non-human animals and methods of use thereof
CN111304246B (zh) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 一种人源化细胞因子动物模型、制备方法及应用
US20230072216A1 (en) * 2020-01-10 2023-03-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric mhc protein complex
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
KR20230074758A (ko) 2020-09-24 2023-05-31 더 잭슨 래보라토리 면역 세포 요법을 평가하기 위한 인간화 마우스 모델
US12376573B2 (en) 2021-03-31 2025-08-05 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire
CN116918766A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人aml小鼠原位pdox模型的建立方法及应用
CN116918767A (zh) * 2022-04-07 2023-10-24 上海立迪生物技术股份有限公司 一种人all小鼠原位pdox模型的建立方法及应用
AU2023310163A1 (en) 2022-07-19 2025-01-16 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system
IL325100A (en) 2023-06-16 2026-02-01 Regeneron Pharma Vectors, genetically modified cells and genetically modified non-human animals containing them
WO2025171307A1 (en) 2024-02-08 2025-08-14 Regeneron Pharmaceuticals, Inc. Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
WO2025212991A1 (en) 2024-04-05 2025-10-09 Regeneron Pharmaceuticals, Inc. Rodent models of disease
WO2025250495A1 (en) * 2024-05-28 2025-12-04 Regeneron Pharmaceuticals, Inc. Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
WO2026096736A1 (en) 2024-10-31 2026-05-07 Regeneron Pharmaceuticals, Inc. Rodents expressing humanized polymeric immunoglobulin receptor

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
WO1988003173A2 (en) 1986-10-24 1988-05-05 Cetus Corporation New forms of colony stimulating factor-1
DE3853201T2 (de) 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
JP2981486B2 (ja) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
JP2935511B2 (ja) * 1989-10-20 1999-08-16 忠三 岸本 ヒトｉｌ―６レセプターの製造方法
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
DE69131331T2 (de) 1990-01-15 2000-03-02 Yeda Research And Development Co., Ltd. Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren
DK0481058T3 (da) 1990-05-03 1996-12-02 Systemix Inc Humant, lymfatisk væv i en immunokompromitteret vært
JPH05500617A (ja) 1990-05-25 1993-02-12 システミックス，インコーポレイティド 免疫処理された宿主におけるヒト末梢血液細胞
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
CA2103705C (en) 1991-02-11 1996-01-30 Ayub K. Ommaya Spinal fluid driven artificial organ
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
DE69229254T2 (de) 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
US5663481A (en) 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
JPH10503092A (ja) 1994-07-27 1998-03-24 メルク エンド カンパニー インコーポレーテッド ブラジキニンｂ２受容体が改変されたトランスジェニック非ヒト動物
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
EP0973381B1 (en) 1997-04-09 2010-03-03 AMDL, Inc. Animal model for evaluation of vaccines
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
JP2003508038A (ja) 1999-08-31 2003-03-04 ジェネンコア インターナショナル インコーポレーテッド ドナー特異的機能性免疫の産生を容易にすることができるトランスジェニック哺乳類
EP1244807A1 (en) 1999-12-09 2002-10-02 Human Genome Sciences, Inc. Il-6 like polynucleotide
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN1553963A (zh) * 2001-07-10 2004-12-08 ǿ����ǿ���о����޹�˾ 用于遗传修饰造血祖细胞的方法和这些被修饰细胞的应用
WO2003039232A2 (en) * 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
WO2003041495A1 (en) 2001-11-15 2003-05-22 Kirin Beer Kabushiki Kaisha Chimeric nonhuman animal
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (zh) 2002-07-13 2008-08-27 上海医学遗传研究所 一种促人血小板生成素表达载体及其构建方法
AU2003278790A1 (en) 2002-09-09 2004-03-29 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
JP2006517096A (ja) 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
AU2004219592C1 (en) * 2003-03-12 2011-02-24 Genentech, Inc. Use of Bv8 and/or EG-VEGF to promote hematopoiesis
US20080311095A1 (en) 2007-05-23 2008-12-18 Sangamo Biosciences, Inc. Methods and compositions for increased transgene expression
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
WO2006044962A1 (en) 2004-10-19 2006-04-27 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PL2019683T5 (pl) 2006-04-25 2022-12-05 The Regents Of The University Of California Podawanie czynników wzrostu do leczenia zaburzeń OUN
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
EP2088854A1 (en) 2006-12-05 2009-08-19 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
WO2009042917A1 (en) 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
KR20120088542A (ko) * 2009-04-13 2012-08-08 아프세스 게엠베하 & 씨오. 카게 종양 치료를 위한 조작된 중간엽 줄기세포 및 이를 사용하는 방법
SG176118A1 (en) * 2009-06-29 2011-12-29 Qingfeng Chen Methods of producing humanized non-human mammals
JP2012531894A (ja) 2009-06-29 2012-12-13 レスコフ，イリヤ，ビー． ヒト血液癌の非ヒト哺乳動物モデル
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8541646B2 (en) 2009-10-06 2013-09-24 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
NO2516457T3 (en:Method) * 2009-12-21 2018-08-11
US9402377B2 (en) 2010-09-20 2016-08-02 Yale University Human SIRPAalpha transgenic animals and their methods of use
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
PT4233537T (pt) 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
PL2818478T3 (pl) * 2011-10-28 2017-09-29 Regeneron Pharmaceuticals, Inc. Humanizowane il-6 i receptor il-6
IN2015DN02032A (en:Method) 2012-09-07 2015-08-14 Univ Yale
ES2884598T3 (es) 2012-11-05 2021-12-10 Regeneron Pharma Animales no humanos modificados genéticamente y métodos de uso de los mismos
MX368931B (es) 2013-09-23 2019-10-22 Regeneron Pharma Animales no humanos que tienen un gen de proteina reguladora de señal humanizado.
AU2014337526B2 (en) 2013-10-15 2020-09-10 Regeneron Pharmaceuticals, Inc. Humanized IL-15 animals
PT3482629T (pt) 2014-05-19 2021-02-18 Univ Yale Animais não humanos geneticamente modificados que expressam epo humana
PT3282835T (pt) 2015-04-13 2023-07-25 Univ Yale Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos

Also Published As

Publication number Publication date
RU2015121195A (ru) 2016-12-27
US20160366862A1 (en) 2016-12-22
EP3308641A1 (en) 2018-04-18
EP3556206B1 (en) 2021-06-02
WO2014071397A3 (en) 2014-06-26
EP3939423A1 (en) 2022-01-19
IL299887A (en) 2023-03-01
KR102649893B1 (ko) 2024-03-25
JP2025010204A (ja) 2025-01-20
MX370856B (es) 2020-01-08
JP6772234B2 (ja) 2020-10-21
IL311744B2 (en) 2025-10-01
JP2021010371A (ja) 2021-02-04
RU2018140189A3 (en:Method) 2022-05-04
MX2019015882A (es) 2020-02-07
IL299887B2 (en) 2024-09-01
EP2914102A2 (en) 2015-09-09
FI3939423T3 (fi) 2024-05-23
PT3556206T (pt) 2021-08-24
IL311744B1 (en) 2025-06-01
HK1210380A1 (en) 2016-04-22
MX2015005654A (es) 2016-04-28
CN108401987A (zh) 2018-08-17
NZ631614A (en) 2016-10-28
PT2914102T (pt) 2018-01-15
JP6422441B2 (ja) 2018-11-14
EP4389764A2 (en) 2024-06-26
AU2022200302B2 (en) 2025-04-10
CN104918483B (zh) 2018-05-11
US20140134662A1 (en) 2014-05-15
MX2020012427A (es) 2022-06-08
JP2015534819A (ja) 2015-12-07
JP7105844B2 (ja) 2022-07-25
CA2887706C (en) 2022-08-02
IL270124A (en:Method) 2019-12-31
KR20210087567A (ko) 2021-07-12
MY175400A (en) 2020-06-24
MX377561B (es) 2025-03-10
JP7579304B2 (ja) 2024-11-07
KR20240042142A (ko) 2024-04-01
FI4389764T3 (fi) 2026-04-24
PT3939423T (pt) 2024-05-29
US11778995B2 (en) 2023-10-10
CN104918483A (zh) 2015-09-16
AU2022200302A1 (en) 2022-02-10
AU2013337242A1 (en) 2015-04-30
EP2914102B1 (en) 2017-10-18
SG11201502685XA (en) 2015-05-28
KR102458016B1 (ko) 2022-10-25
US20240099278A1 (en) 2024-03-28
KR20220148307A (ko) 2022-11-04
RU2673156C2 (ru) 2018-11-22
KR102275412B1 (ko) 2021-07-12
IL270124B2 (en) 2023-06-01
KR20150081285A (ko) 2015-07-13
IL311744A (en) 2024-05-01
US9901082B2 (en) 2018-02-27
PT3308641T (pt) 2019-10-24
CN114766432B (zh) 2024-08-02
ES2655442T3 (es) 2018-02-20
EP3556206A1 (en) 2019-10-23
WO2014071397A2 (en) 2014-05-08
JP2019037238A (ja) 2019-03-14
AU2019204775B2 (en) 2021-10-21
DK2914102T3 (en) 2017-12-11
AU2019204775A1 (en) 2019-07-25
US10785968B2 (en) 2020-09-29
IL238478B (en) 2018-05-31
IL258968B (en) 2019-10-31
CA2887706A1 (en) 2014-05-08
NZ749626A (en) 2023-11-24
KR20220075242A (ko) 2022-06-07
AU2013337242B2 (en) 2019-04-04
KR102768101B1 (ko) 2025-02-18
ES2983031T3 (es) 2024-10-21
EP3939423B1 (en) 2024-03-06
NO2946162T3 (en:Method) 2018-06-09
EP4389764A3 (en) 2024-08-14
DK3556206T3 (da) 2021-08-09
ES2748662T3 (es) 2020-03-17
ES2884598T3 (es) 2021-12-10
IL258968A (en) 2018-06-28
DK3308641T3 (da) 2019-10-07
NZ724353A (en) 2022-05-27
IL238478A0 (en) 2015-06-30
DK4389764T3 (da) 2026-04-13
EP4389764B1 (en) 2026-03-18
JP2022132376A (ja) 2022-09-08
CN108401987B (zh) 2022-04-29
SG10201707449TA (en) 2017-10-30
CN114766432A (zh) 2022-07-22
US20180049413A1 (en) 2018-02-22
KR102402806B1 (ko) 2022-05-30
RU2018140189A (ru) 2018-12-10
US20210100228A1 (en) 2021-04-08
DK3939423T3 (da) 2024-05-06
HK1253909A1 (en) 2019-07-05
US9986724B2 (en) 2018-06-05
IL299887B1 (en) 2024-05-01
EP3308641B1 (en) 2019-07-03

Similar Documents

Publication Publication Date Title
IL270124A (en:Method)
BR112014017635A2 (en:Method)
BR112014017614A2 (en:Method)
BR112014019099A2 (en:Method)
BR112014017625A2 (en:Method)
BR112014017659A2 (en:Method)
BR112014017592A2 (en:Method)
BR112014017968A2 (en:Method)
BR112014017638A2 (en:Method)
AR092201A1 (en:Method)
BR112014017609A2 (en:Method)
BR112014019426A2 (en:Method)
BR112014017644A2 (en:Method)
BR112014013184A8 (en:Method)
BR112014017618A2 (en:Method)
BR112014017652A2 (en:Method)
BR112014017630A2 (en:Method)
BR112014017621A2 (en:Method)
BR112014017631A2 (en:Method)
BR112014017641A2 (en:Method)
BR112014017622A2 (en:Method)
BR112014017589A2 (en:Method)
BR112014017600A2 (en:Method)
BR112014017636A2 (en:Method)
BR112014017667A2 (en:Method)